BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

GeneTex Antibody Company to Launch a New Primary Antibody for the Detection of Oxidized CaMKII


10/23/2012 9:30:10 AM

IRVINE, Calif., Oct. 22, 2012 /PRNewswire/ -- GeneTex Inc., a leading manufacturer of antibodies and antibody-related reagents, is set to launch a new antibody that can detect the oxidized form of calmodulin-dependent protein kinase II (CaMKII), which can be used to characterize and diagnose various diseases.

(Logo: http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b)

The activation of CaMKII through oxidation is associated with a variety of conditions including heart failure, cardiac arrhythmias, cancer, neurological disease and sepsis. Indeed, CaMKII oxidation increases during myocardial ischemia and infarction, and CaMKII oxidation has been shown to play a pivotal role in cardiac cell death during angiotensin II-mediated apoptosis (Erickson et.al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133(3):462-74 (2008)).

While previous methods of measuring oxidative stress have relied on "bystander" molecules that are not directly implicated in disease pathogenesis, GeneTex's new antibody against oxidized CaMKII will allow researchers to track the oxidation of a biologically active molecule present in blood or biopsy specimens. This antibody has been shown to detect oxidized CaMKII in blood from mice with premature aging due to the knockout of methionine sulfoxide reductase A, mice injected with bacterial endotoxin (a model of sepsis), mice injected with angiotensin II, mice fed a pro-oxidant diet and untreated mice with cancer, as well as mice that had been treated with experimental therapies.

GeneTex is pleased to introduce this antibody against oxidized CaMKII to researchers worldwide. This antibody has been validated for western blotting and immunohistochemistry using both frozen and paraffin-embedded sections and was used to detect oxidized CaMKII in the aforementioned publication in Cell. For additional information on GeneTex's new CaMKII antibody, call toll-free 877-GENETEX (436-3839) or visit http://www.genetex.com/CaMKII-oxidized-antibody-GTX36254.html.

About GeneTex:

GeneTex is an antibody manufacturing company that was founded by a group of renowned academic scientists in 1997. GeneTex strives to produce the highest quality antibodies and reagents. Their primary antibodies and secondary antibodies are created through a process involving extensive research, development and validation.

SOURCE GeneTex


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->